Physicians' and patients' adherence to antiretroviral prophylaxis after sexual exposure to HIV: Results from South-Eastern France

AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV

Volumn 20, Issue 5, 2008, Pages 537-541

  Rey, Dominique ^a,b,c   Bendiane, Marc Karim ^a,b,c   Bouhnik, Anne Deborah ^a,b,c   Almeda, Jesus ^d   Moatti, Jean Paul ^a,b   Carrieri, Maria Patrizia ^a,b,c  

^a AIX MARSEILLE UNIV   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Adherence; Antiretroviral treatment; HIV; Post exposure prophylaxis; Sexual exposure

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASTHENIA; CONSULTATION; DIARRHEA; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; FRANCE; HEALTH SURVEY; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; PATIENT COMPLIANCE; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; SEXUAL CRIME; SEXUAL INTERCOURSE; SEXUAL TRANSMISSION; SEXUALITY; SIDE EFFECT; VOMITING; ADOLESCENT; CLINICAL TRIAL; DRUG ADMINISTRATION ROUTE; MIDDLE AGED; MULTICENTER STUDY; PROFESSIONAL PRACTICE; PSYCHOLOGICAL ASPECT; SEXUAL BEHAVIOR; STANDARD; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; DRUG ADMINISTRATION ROUTES; FEMALE; FRANCE; GUIDELINE ADHERENCE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PRACTICE GUIDELINES AS TOPIC; PROFESSIONAL PRACTICE; SEX OFFENSES; SEXUAL BEHAVIOR; TREATMENT OUTCOME;

EID: 46749091740     PISSN: 09540121     EISSN: 13600451     Source Type: Journal    
DOI: 10.1080/09540120701867198     Document Type: Article

References (21)

1. Almeda, J., Casabona, J., Simon, B., Gerard, M., Rey, D., Puro, V., et al. (2004). Proposed recommendations for the management of HIV post-exposure prophylaxis after sexual, injecting drug or other exposures in Europe. Euro Surveillance, 9(6), 35-40.
2. Beltzer, N., Lagarde, M., Wu-Zhou, X., Vongmany, N., & Grémy, I. (2005). [Knowledge, attitudes, behaviours and practises towards HIV/AIDS in France: Evolutions 1992-1994-1998-2001-2004] [in French]. Paris: Observatoire Régional de la Santé Ile-de-France.
3. Carrieri, M.P., Bendiane, M.K., Moatti, J.P., & Rey, D. (2006). Access to HIV prophylaxis for survivors of sexual assault: The tip of the iceberg. Antiviral Therapy, 11, 391-392.
4. CDC. (2005). Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States MMRW, 54(RR-2), 1-19.
5. Circulaire 98/228. (1998). Paris: French Ministry of Employment and Solidarity [in French].
6. Circulaire no 2003/165. (2003). DGS/DHOS/DRT/DSS. Circulaire no 2003/165 of April, 2th 2003 relating to the recommendations of implementation of a antiretroviral treatment after exposure to the risk of transmission of HIV [in French].
7. Day, S., Mears, A., Bond, K., & Kulasegaram, R. (2006). Post-exposure HIV prophylaxis following sexual exposure: a retrospective audit against recent draft BASHH guidance. Sexually Transmitted Infections, 82(3), 236-237.
8. Grob, P.M., Cao, Y., Muchmore, E., Ho, D.D., Norris, S., Pav, J.W., et al. (1997). Prophylaxis against HIV-1 infection in chimpanzees by nevirapine, a nonnucleoside inhibitor of reverse transcriptase. Nature Medicine, 3(6), 665-670.
9. Herida, M., Larsen, C., Lot, F., Laporte, A., Desenclos, J.C., & Hamers, F.F. (2006). Cost-effectiveness of HIV post-exposure prophylaxis in France. Aids, 20(13), 1753-1761.
10. Kahn, J.O., Martin, J.N., Roland, M.E., Bamberger, J.D., Chesney, M., Chambers, D., et al. (2001). Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: The San Francisco PEP Study. The Journal of Infectious Diseases, 183(5), 707-714.
11. Laporte, A., Jourdan, N., Bouvet, E., Lamontagne, F., Pillonel, J., & Desenclos, J.C. (2002). Post-exposure prophylaxis after non-occupational HIV exposure: Impact of recommendations on physicians' experiences and attitudes. Aids, 16(3), 397-405.
12. Lert, F., Dray Spira, R., Sitta, R., Obadia, Y., Spire, B., Peretti-Wattel, P., & the vespa group. (2005). [First results from the ANRS-VESPA survey of persons living with HIV/AIDS]. Revue d'Epidemiologie et de Sante Publique, 53(1), 79-85.
13. Martin, J.N., Roland, M.E., Neilands, T.B., Krone, M.R., Bamberger, J.D., Kohn, R.P., et al. (2004). Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior. Aids, 18(5), 787-792.
14. NSW Department of Health. (1998). Management of non-occupational exposure to blood borne and sexually transmissible diseases. Sydney: NSW Department of Health.
15. Pinkerton, S.D., Martin, J.N., Roland, M.E., Katz, M.H., Coates, T.J., & Kahn, J.O. (2004). Cost-effectiveness of HIV postexposure prophylaxis following sexual or injection drug exposure in 96 metropolitan areas in the United States. Aids, 18(15), 2065-2073.
16. Puro, V., Cicalini, S., De Carli, G., Soldani, F., Antunes, F., Balslev, U., et al. (2004). Post-exposure prophylaxis of HIV infection in healthcare workers: recommendations for the European setting. European Journal of Epidemiology, 19(6), 577-584.
17. Rey, D., Bendiane, M.K., Moatti, J.P., Wellings, K., Danziger, R., & MacDowall, W. (2000). Post-exposure prophylaxis after occupational and non-occupational exposures to HIV: an overview of the policies implemented in 27 European countries. AIDS Care, 12(6), 695-701.
18. Rey, D., Marimoutou, C., Bouhnik, A.D., Dray-Spira, R., Lert, F., & Obadia, Y. (2004). Knowledge of HIV postexposure prophylaxis in a population of HIV-positive outpatients: results of a French national survey. Journal of Acquired Immune Deficiency Syndromes, 35(4), 393-400.
19. Roland, M.E., Neilands, T.B., Krone, M.R., Katz, M.H., Franses, K., Grant, R.M., et al. (2005). Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clinical Infectious Diseases, 41(10), 1507-1513.
20. Sonder, G.J., Regez, R.M., Brinkman, K., Prins, J.M., Mulder, J.W., Spaargaren, J., et al. (2005). Prophylaxis and follow-up after possible exposure to HIV, hepatitis B virus, and hepatitis C virus outside hospital: evaluation of policy 2000-3. BMJ, 330(7495), 825-829.
21. Wade, N.A., Birkhead, G.S., Warren, B.L., Charbonneau, T.T., French, P.T., Wang, L., et al. (1998). Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. New England Journal of Medicine, 339(20), 1409-1414.